NEU · ASX

Neuren Pharmaceuticals Limited (ASX:NEU)

AU$12.26

 -0.04 (-0.325%)
ASX:Live
19/03/2025 04:10:19 PM
Recent Earnings downgrade HALO Small HALO Ords HALO Balance Sheet HALO 200 +4
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

NEU Overview

NEU Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Very Strong

Valuation

Value

Consensus

Momentum

Price

Neutral

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Neutral

Balance Sheet

Very Weak

About NEU

Website

Neuren Pharmaceuticals Limited

Telephone

61.3.9092.0480

Address

Suite 201 697 Burke Road Camberwell, Victoria (VIC) 3124

Description

Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. Its products include Pipeline, Trofinetide, and NNZ-2591. The company was founded on December 17, 2001 and is headquartered in Camberwell, Australia.

NEU Price Chart

Key Stats

Market Cap

AU$1.56B

PE

11.90

EV/EBITDA

9.6

Dividends Overview

DIV Yield

.0%

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 10.9 - 24.0

Trade Value (12mth)

AU$1,957,409.00

1 week

11.51%

1 month

-8.28%

YTD

0.41%

1 year

-40.03%

All time high

25.95

Key Fundamentals

EPS 3 yr Growth

-1779.30%

EBITDA Margin

82.30%

Operating Cashflow

-$11m

Free Cash Flow Return

-4.00%

ROIC

49.90%

Interest Coverage

N/A

Quick Ratio

8.70

Other Data

Shares on Issue (Fully Dilluted)

131m

HALO Sector

Healthcare

Next Company Report Date

26-Feb-26

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

4.02

NEU Announcements

Latest Announcements

Date Announcements

19 March 25

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

18 March 25

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

17 March 25

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

14 March 25

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

13 March 25

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

12 March 25

Becoming a substantial holder

×

Becoming a substantial holder

12 March 25

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

11 March 25

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

11 March 25

Application for quotation of securities - NEU

×

Application for quotation of securities - NEU

10 March 25

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

07 March 25

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

07 March 25

Notification of cessation of securities - NEU

×

Notification of cessation of securities - NEU

06 March 25

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

06 March 25

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

05 March 25

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

04 March 25

Update - Notification of buy-back - NEU

×

Update - Notification of buy-back - NEU

03 March 25

Notification of cessation of securities - NEU

×

Notification of cessation of securities - NEU

28 February 25

Appendix 4E and 2024 full year accounts

×

Appendix 4E and 2024 full year accounts

28 February 25

2024 results - A$166m comprehensive income for shareholders

×

2024 results - A$166m comprehensive income for shareholders

28 February 25

Neuren receives DAYBUE sales milestone payment of US$50m

×

Neuren receives DAYBUE sales milestone payment of US$50m

28 February 25

2024 Full Year Results webinar

×

2024 Full Year Results webinar

27 February 25

DAYBUE (trofinetide) 2024 net sales US$348 million

×

DAYBUE (trofinetide) 2024 net sales US$348 million

27 February 25

Neuren 2024 results investor webinar on 28 February 2025

×

Neuren 2024 results investor webinar on 28 February 2025

25 February 25

Becoming a substantial holder

×

Becoming a substantial holder

24 February 25

Neuren receives Rare Pediatric Disease Designation from FDA

×

Neuren receives Rare Pediatric Disease Designation from FDA

NEU Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock 0.00 1.24 1.11 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock 0.00 1.20 1.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock 102.3 82,313.3 -10.1 Lock Lock Lock
     PE X Lock Lock Lock Lock 1,826.7 14.3 11.9 Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 334.9 11.3 9.6 Lock Lock Lock
CFPS $ Lock Lock Lock Lock 0.02 1.27 1.18 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock 0.03 1.41 -0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock 142.7 5,119.7 -7.0 Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.3 5.7 -0.7 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.33 1.61 2.87 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.33 1.61 2.87 Lock Lock Lock
     Growth % Lock Lock Lock Lock 8.5 388.4 77.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 129 131 131 Lock Lock Lock
Basic m Lock Lock Lock Lock 126 127 128 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 15 232 213 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A 1,493.7 -8.1 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 16 33 38 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 15 0 213 Lock Lock Lock
     Growth % Lock Lock Lock Lock 181,887.5 -100.0 N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock 99.9 0.0 100.0 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -2 199 176 Lock Lock Lock
     Growth % Lock Lock Lock Lock 86.1 12,662.7 -11.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -10.9 85.9 82.3 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -2 199 176 Lock Lock Lock
     Growth % Lock Lock Lock Lock 86.0 12,583.0 -11.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -11.0 85.9 82.3 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -1 205 183 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 48 41 Lock Lock Lock
Net Income $m Lock Lock Lock Lock 0 157 142 Lock Lock Lock
     Growth % Lock Lock Lock Lock 102.4 85,270.1 -9.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock 1.3 67.7 66.6 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock 4 185 -11 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -211 4 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 0 4 -9 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock 4 185 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock 135.9 5,064.4 -106.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock 0.2 0.8 -0.1 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 71 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 40 229 222 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 43 248 410 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -40 -229 -222 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 2 43 46 Lock Lock Lock
Equity $m Lock Lock Lock Lock 42 205 364 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 42 205 364 Lock Lock Lock
     Growth % Lock Lock Lock Lock 6.0 393.4 77.3 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock 0.4 63.3 34.7 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 0.4 76.5 39.0 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -3.9 161.5 61.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock 0.5 127.3 49.9 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock 8.9 149.9 -4.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 25.3 -1.1 -1.3 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -96.6 -111.4 -61.1 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 25.8 5.8 8.7 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 25.8 5.8 8.7 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 92.9 92.5 55.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock 214.5 432.4 -24.6 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 11.6 29.9 2.2 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.4 1.1 0.6 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 1.8 0.3 0.7 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.3 0.9 0.5 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.3 0.9 0.5 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -4.7 88.4 85.8 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -1.6 82.7 44.7 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 23.4 22.4 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock 0.4 63.3 34.7 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.2 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock 0.4 76.5 39.0 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock 0.4 76.5 39.0 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 31.5 12.2 162.4 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 31.5 12.2 162.4 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 9,170.9 0.0 17,632.9 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -9,139.3 12.2 -17,470.5 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

.0%

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

4.02%

Value ($M)

57

Prior Change

0.10%

7 Day Change

-0.50%

1 Month Change

-0.20%

3 Month Change

-0.30%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

NEU Shortsell

Frequently Asked Questions

The current share price of Neuren Pharmaceuticals Limited (NEU:ASX) is AU$12.26.
The 52-week high share price for Neuren Pharmaceuticals Limited (NEU:ASX) is AU$24.00.
The 52-week low share price for Neuren Pharmaceuticals Limited (NEU:ASX)? is AU$10.90.
The current TTM dividend payout for Neuren Pharmaceuticals Limited (NEU:ASX) is 0.00.
Neuren Pharmaceuticals Limited (NEU:ASX) does not pay a dividend.
Neuren Pharmaceuticals Limited (NEU:ASX) has a franking level of 0.0%.
Neuren Pharmaceuticals Limited (NEU:ASX) is classified in the Healthcare.
The current P/E ratio for Neuren Pharmaceuticals Limited (NEU:ASX) is 11.90.
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.